POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES
Domain expertise, global resource, long-term capital
PORTFOLIO NEWS
Abbisko Therapeutics, an innovative biopharmaceutical company based in Shanghai Zhangjiang High...PHILADELPHIA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc., a genetic medicines company...CAMBRIDGE, Mass. and NEW YORK, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc....TPST-1495 is a selective dual antagonist of both EP2 and EP4 prostaglandin receptors. Lyfe...Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated...December 28, 2019, Shanghai, China, Elpiscience Biopharma announces the completion of Series B...- FasTCAR-19 (GC007F) shows a high response rate, with 34 of 35 evaluable r/r B-ALL patients...Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the...More Posts
Company
Shanghai
Room2909-14, 168 Hubin Road, Huangpu District, Shanghai, China.
Hong Kong
Unit 902-904, Two ChinaChem Central, 26 Des Voeux Road Central, Hong Kong
US
2730 Sand Hill Road, Suite 130, Menlo Park, CA
All Posts
×
LillyAsiaVentures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
http://user-assets.sxlcdn.com/images/315509/FnksTvTDur7jpExbqYminmtjWgoM.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png